DK2395018T3 - Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf - Google Patents
Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf Download PDFInfo
- Publication number
- DK2395018T3 DK2395018T3 DK11170742.8T DK11170742T DK2395018T3 DK 2395018 T3 DK2395018 T3 DK 2395018T3 DK 11170742 T DK11170742 T DK 11170742T DK 2395018 T3 DK2395018 T3 DK 2395018T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- val
- thr
- gly
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Gram-positive bacteria
- C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (10)
1. Humant monoklonalt antistof, der binder specifikt til og har opsonisk fagocytisk dræberaktivitet mod mindst to forskellige Staphylococcus-arter og mod mindst 3 forskellige stammer af Staphylococcus aureus, der er kendetegnet ved, at antistoffet er et antistof med en tung kæde, der omfatter den variable region ifølge SEQ ID NO: 155, og en let kæde, der omfatter den variable region ifølge SEQ ID NO: 215.
2. Humant monoklonalt antistof ifølge krav 1, der er kendetegnet ved, at det har den opsoniske fagocytiske dræberaktivitet, når Staphylococcus-arten er i logaritmisk vækstfase og i statisk fase.
3. Humant monoklonalt antistof ifølge krav 1 eller 2, der er kendetegnet ved, at Staphylococcus-arten er udvalgt fra gruppen, der består af S. aureus, S. auricularis, S. capitis, S. caprae, S. caseolyticus, S. chromogenes, S. cohnii, S. epidermidis, S. haemolyticus, S. hominis, S. hyicus, S. intermedium, S. lentus, S. lugdunensis, S. saprophyticus, S. schleiferi, S. sciuri, S. simulans, S. warneri og S. xylosus.
4. Immunkonjugat, der omfatter et humant monoklonalt antistof ifølge et hvilket som helst af kravene 1-3, hvilket immunkonjugat yderligere omfatter mindst ét tag.
5. Nukleinsyremolekyle, der koder for et humant monoklonalt antistof ifølge et hvilket som helst af kravene 1-3.
6. Vektor, der omfatter et nukleinsyremolekyle ifølge krav 5.
7. Værtscelle, der omfatter en vektor ifølge krav 6.
8. Fremgangsmåde til fremstilling af et humant monoklonalt antistof ifølge et hvilket som helst af kravene 1-3, hvor fremgangsmåden omfatter trinene: a) dyrkning af en værtscelle ifølge krav 7 under betingelser, der bidrager til ekspression af det humane monoklonale antistof, og eventuelt b) indvindning af det udtrykte humane monoklonale antistof.
9. Farmaceutisk sammensætning, der omfatter et humant monoklonalt antistof ifølge et hvilket som helst af kravene 1-3 hvilken farmaceutiske sammensætning yderligere omfatter mindst ét farmaceutisk acceptabelt excipiens.
10. Farmaceutisk sammensætning ifølge krav 9, der yderligere omfatter mindst ét andet terapeutisk middel.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81147706P | 2006-06-06 | 2006-06-06 | |
| EP06124231 | 2006-11-16 | ||
| EP07103584 | 2007-03-06 | ||
| EP07765322.8A EP2027155B1 (en) | 2006-06-06 | 2007-06-05 | Human binding molecules having killing activity against staphylococci and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2395018T3 true DK2395018T3 (da) | 2016-04-25 |
Family
ID=44951549
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07765322.8T DK2027155T3 (da) | 2006-06-06 | 2007-06-05 | Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf |
| DK11170742.8T DK2395018T3 (da) | 2006-06-06 | 2007-06-05 | Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07765322.8T DK2027155T3 (da) | 2006-06-06 | 2007-06-05 | Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8211431B2 (da) |
| EP (3) | EP2395018B1 (da) |
| JP (2) | JP5574706B2 (da) |
| KR (1) | KR101508390B1 (da) |
| CN (2) | CN103351435B (da) |
| AU (1) | AU2007255384B2 (da) |
| CA (2) | CA2881717C (da) |
| DK (2) | DK2027155T3 (da) |
| EA (2) | EA031202B1 (da) |
| HU (1) | HUE027099T2 (da) |
| IL (1) | IL195675A (da) |
| MX (1) | MX2008014977A (da) |
| NZ (1) | NZ572773A (da) |
| SI (1) | SI2395018T1 (da) |
| WO (1) | WO2007141274A2 (da) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| PL2314621T3 (pl) * | 2004-05-27 | 2014-08-29 | Crucell Holland Bv | Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania |
| JP4852046B2 (ja) * | 2004-10-12 | 2012-01-11 | クルセル ホランド ベー ヴェー | 癌の治療及び検出に用いる結合分子 |
| CA2608058C (en) | 2005-05-12 | 2013-09-10 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| US7960518B2 (en) | 2006-06-06 | 2011-06-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
| DK2027155T3 (da) | 2006-06-06 | 2016-05-09 | Crucell Holland Bv | Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| CA2674382C (en) * | 2007-01-03 | 2016-05-31 | Morphotek, Inc. | High affinity antibodies that neutralize staphylococcus enterotoxin b |
| KR20100021577A (ko) * | 2007-05-31 | 2010-02-25 | 머크 앤드 캄파니 인코포레이티드 | 에스.아우레우스 ＯＲＦ0657ｎ을 표적화하는 항원 결합 단백질 |
| CN102666583B (zh) | 2009-07-15 | 2015-11-25 | Aimm医疗股份公司 | 革兰氏阳性细菌特异性结合化合物 |
| EP2284193A1 (en) * | 2009-08-10 | 2011-02-16 | Kenta Biotech AG | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| JP2015534997A (ja) | 2012-10-25 | 2015-12-07 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ＥｒｂＢ３と結合する抗原結合タンパク質 |
| AU2014363987A1 (en) * | 2013-12-09 | 2016-06-30 | Janssen Biotech, Inc. | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| ES2754209T3 (es) | 2013-12-13 | 2020-04-16 | Stora Enso Oyj | Cartón multicapa |
| WO2015088346A1 (en) * | 2013-12-13 | 2015-06-18 | Rijksuniversiteit Groningen | Antibodies against staphylococcus aureus and uses thereof. |
| JP2018517708A (ja) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 |
| CN114853891A (zh) | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| US20170073397A1 (en) * | 2015-08-24 | 2017-03-16 | Medimmune, Llc | MrkA Polypeptides, Antibodies, and Uses Thereof |
| PE20181367A1 (es) * | 2015-09-30 | 2018-08-27 | Janssen Biotech Inc | Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso |
| LT3535298T (lt) | 2016-11-02 | 2021-12-27 | Jounce Therapeutics, Inc. | Antikūnai prieš pd-1 ir jų panaudojimas |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CN114728179A (zh) * | 2019-08-19 | 2022-07-08 | 潘迪恩运营公司 | 利用pd-1激动剂的靶向免疫耐受 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| CN111505299B (zh) * | 2020-04-29 | 2022-09-06 | 上海理工大学 | 一种人葡萄球菌免疫胶体金快速检测试纸条 |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
| CA3217279A1 (en) * | 2021-05-04 | 2022-11-10 | Olga Ignatovich | Anti-tigit antibodies and methods of use thereof |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN114805584B (zh) * | 2022-06-30 | 2022-09-09 | 上海优替济生生物医药有限公司 | 抗原结合蛋白及其用途 |
| CN118580347B (zh) * | 2024-05-13 | 2025-02-07 | 重庆原伦生物科技有限公司 | 一种抗金黄色葡萄球菌蛋白a的单克隆抗体及其应用 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529700A (en) | 1982-08-20 | 1985-07-16 | University Of Miami | Hybridoma cells secreting a monoclonal antibody specific for 5-bromo and 5-iodoeoxyuridine and reagents for measuring cellular proliferation |
| US4625015A (en) * | 1982-08-23 | 1986-11-25 | Scripps Clinic & Research Foundation | Broad spectrum influenza antisera |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4901307A (en) * | 1986-10-17 | 1990-02-13 | Qualcomm, Inc. | Spread spectrum multiple access communication system using satellite or terrestrial repeaters |
| JPS6436463A (en) | 1987-07-31 | 1989-02-07 | Toshiba Corp | Information processing system |
| US6184024B1 (en) * | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| ES2062364T3 (es) | 1989-06-08 | 1994-12-16 | Wistar Inst | Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia. |
| US6248574B1 (en) | 1989-12-13 | 2001-06-19 | Avigdor Shaffermann | Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides |
| DE4006630A1 (de) | 1990-03-03 | 1991-09-12 | Behringwerke Ag | Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung |
| US5103459B1 (en) * | 1990-06-25 | 1999-07-06 | Qualcomm Inc | System and method for generating signal waveforms in a cdma cellular telephone system |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| US5494671A (en) * | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
| EP0872553B1 (en) | 1991-09-19 | 2000-11-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES | Chimeric and/or growth-restricted flaviviruses |
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| NL9101953A (nl) | 1991-11-21 | 1993-06-16 | Seed Capital Investments | Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen. |
| US5589174A (en) * | 1992-09-17 | 1996-12-31 | Takara Shuzo Co., Ltd. | Anti-human influenza virus antibody |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| HU219503B (hu) | 1994-07-08 | 2001-04-28 | Baxter Aktiengesellschaft | Javított vakcina TBE-vírusfertőzés elleni immunizálásra, valamint eljárás az előállítására |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| GB2310972B (en) | 1996-03-07 | 2000-06-14 | Motorola Ltd | Communication system and operating method thereof |
| US6455509B1 (en) * | 1996-06-04 | 2002-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Dengue nucleic acid vaccines that induce neutralizing antibodies |
| EP0947581A4 (en) | 1996-08-08 | 2004-07-28 | Mitsubishi Pharma Corp | CULTURAL MEDIUM AND ITS USE. |
| EP0934526B1 (en) | 1996-10-08 | 2003-01-08 | U-BISys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
| US5886988A (en) | 1996-10-23 | 1999-03-23 | Arraycomm, Inc. | Channel assignment and call admission control for spatial division multiple access communication systems |
| US6335922B1 (en) * | 1997-02-11 | 2002-01-01 | Qualcomm Incorporated | Method and apparatus for forward link rate scheduling |
| ES2345614T3 (es) | 1997-02-28 | 2010-09-28 | Sanofi Pasteur Biologics Co. | Vacunas quimericas de flavivirus. |
| US5914950A (en) * | 1997-04-08 | 1999-06-22 | Qualcomm Incorporated | Method and apparatus for reverse link rate scheduling |
| US20030148463A1 (en) * | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
| US6094428A (en) * | 1997-04-30 | 2000-07-25 | Motorola, Inc. | Method and apparatus for transmission and reception of a transmission rate in a CDMA communication system |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
| US6756361B1 (en) | 1997-10-14 | 2004-06-29 | Nabi | Enterococcus antigens and vaccines |
| EP1047448B1 (en) | 1997-11-20 | 2006-02-01 | United States Army Medical Research and Materiel Command | Dna vaccines against tick-borne flaviviruses |
| KR100279944B1 (ko) * | 1997-12-09 | 2001-02-01 | 윤종용 | 씨디엠에이셀룰러시스템에서의왈쉬코드그룹할당방법 |
| BR9913333A (pt) * | 1998-08-25 | 2001-05-15 | Univ Yale | Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos |
| US6416763B1 (en) * | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
| JP2000078146A (ja) | 1998-08-28 | 2000-03-14 | Nippon Telegr & Teleph Corp <Ntt> | Ａｂｒサービス用無線回線制御方法および該方法を用いた無線基地局と移動端末 |
| US6685948B1 (en) * | 1998-09-02 | 2004-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines |
| AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| ES2378272T3 (es) | 1999-04-15 | 2012-04-10 | Crucell Holland B.V. | Producción de proteína recombinante en una célula humana |
| JP2003503015A (ja) * | 1999-05-03 | 2003-01-28 | メダレツクス・インコーポレーテツド | スタフィロコッカス・アウレウスに対するヒト抗体 |
| US6908994B1 (en) * | 1999-05-10 | 2005-06-21 | The Texas A&M University System | Collagen-binding proteins from enterococcal bacteria |
| US6432411B1 (en) * | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
| AU1778001A (en) * | 1999-11-17 | 2001-05-30 | University Of Rochester | Human ex vivo immune system |
| US7425437B2 (en) * | 1999-11-26 | 2008-09-16 | Crucell Holland B.V. | Vaccines against West Nile Virus |
| EP1134994A1 (en) | 2000-03-15 | 2001-09-19 | Lucent Technologies Inc. | Load balancing based on Walsh code usage |
| EP1267930A4 (en) * | 2000-03-17 | 2005-01-19 | Inhibitex Inc | CROSS-REACTION DISPLACEMENT ANTIBODIES FROM COLLAGEN BINDING PROTEINS AND METHOD OF IDENTIFICATION AND USE |
| US20040013672A1 (en) * | 2000-05-16 | 2004-01-22 | Thomas Jefferson University | Recombinant antibodies, and compositions and methods for making and using the same |
| PE20020132A1 (es) * | 2000-06-29 | 2002-03-04 | Abbott Lab | Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos |
| WO2002015664A2 (en) * | 2000-08-23 | 2002-02-28 | The New York Hospital Medical Center Of Queens | Methods of preventing or treating west nile virus and other infections |
| US20050196755A1 (en) * | 2000-11-17 | 2005-09-08 | Maurice Zauderer | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| US20020090606A1 (en) * | 2001-01-08 | 2002-07-11 | Sandy Stewart | Method and specific phage library for high throughput proteomics |
| US20030148261A1 (en) * | 2001-03-12 | 2003-08-07 | Erol Fikrig | Compositions and methods comprising West Nile virus polypeptides |
| US7329530B2 (en) * | 2001-06-15 | 2008-02-12 | Crucell Holland B.V. | Chimaeric phages |
| ES2435095T3 (es) * | 2001-07-27 | 2013-12-18 | Zoetis W Llc | Vacuna del Nilo Occidental |
| US20030224000A1 (en) * | 2001-12-21 | 2003-12-04 | Kokai-Kun John Fitzgerald | Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| US20040052779A1 (en) * | 2001-12-21 | 2004-03-18 | Stinson Jeffrey R. | Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria |
| JP2005524624A (ja) * | 2001-12-21 | 2005-08-18 | バイオシネクサス インコーポレーテッド | グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体 |
| US20040258699A1 (en) * | 2002-02-11 | 2004-12-23 | Bowdish Katherine S. | Immunotherapeutics for biodefense |
| AU2003213022A1 (en) * | 2002-02-11 | 2003-09-22 | Alexion Pharmaceuticals, Inc. | Immunotherapeutics for biodefense |
| ES2295639T3 (es) * | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| DK1520008T3 (da) * | 2002-07-09 | 2012-10-15 | Baxter Int | Medium frit for dyreprotein til dyrkning af celler |
| US6875433B2 (en) * | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| BR0315935A (pt) * | 2002-10-31 | 2005-09-20 | Health Research Inc | Teste de diagnóstico para o vìrus do nilo ocidental |
| WO2004043405A2 (en) | 2002-11-12 | 2004-05-27 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
| EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
| US20100069614A1 (en) * | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| WO2004111081A2 (en) * | 2003-06-13 | 2004-12-23 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
| WO2005012337A2 (en) * | 2003-07-15 | 2005-02-10 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
| US20070025992A1 (en) * | 2003-07-18 | 2007-02-01 | Mochida Pharmaceutical Co., Ltd | Monoclonal antibody against platelet membrane glycoprotein VI |
| EP1646645A1 (en) * | 2003-07-21 | 2006-04-19 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
| AU2004260884B2 (en) * | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| WO2005047459A2 (en) * | 2003-08-04 | 2005-05-26 | University Of Massachusetts | Sars nucleic acids, proteins, antibodies, and uses thereof |
| EP1692276B1 (en) * | 2003-11-19 | 2010-07-21 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of inducing memory b cell development and terminal differentiation |
| CN1914226B (zh) * | 2003-11-25 | 2012-02-01 | 达纳-法伯癌症研究院有限公司 | SARS-CoV抗体及其使用方法 |
| PL1745075T3 (pl) * | 2004-04-21 | 2013-09-30 | Brigham & Womens Hospital Inc | Peptydy wiążące poli-N-acetyloglukozaminę (PNAG/DPNAG) i sposoby ich zastosowania |
| US7074555B2 (en) * | 2004-04-28 | 2006-07-11 | Idexx Laboratories, Inc. | Detection of West Nile Virus |
| PL2314621T3 (pl) * | 2004-05-27 | 2014-08-29 | Crucell Holland Bv | Cząsteczki wiążące zdolne do neutralizowania wirusa wścieklizny i ich zastosowania |
| CA2571404A1 (en) * | 2004-06-21 | 2005-12-29 | Washington University | Antibodies against west nile virus and therapeutic and prophylactic uses thereof |
| WO2006031825A2 (en) * | 2004-09-13 | 2006-03-23 | Macrogenics, Inc. | Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof |
| JP4852046B2 (ja) * | 2004-10-12 | 2012-01-11 | クルセル ホランド ベー ヴェー | 癌の治療及び検出に用いる結合分子 |
| US7498419B2 (en) * | 2004-10-14 | 2009-03-03 | Washington University | Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody |
| SG159542A1 (en) * | 2004-11-11 | 2010-03-30 | Crucell Holland Bv | Compositions against sars-coronavirus and uses thereof |
| WO2006056006A1 (en) * | 2004-11-23 | 2006-06-01 | The University Of Queensland | Equine west nile virus immunotherapy |
| CA2591665C (en) | 2004-12-20 | 2015-05-05 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
| WO2006136601A1 (en) * | 2005-06-23 | 2006-12-28 | Crucell Holland B.V. | Optimization of west nile virus antibodies |
| AU2006290736B2 (en) * | 2005-09-15 | 2011-09-15 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
| CN1320125C (zh) * | 2005-09-28 | 2007-06-06 | 兰州生物制品研究所 | 一种单克隆抗体的制备方法及其应用 |
| US7960518B2 (en) * | 2006-06-06 | 2011-06-14 | Crucell Holland B.V. | Human binding molecules having killing activity against enterococci and uses thereof |
| DK2027155T3 (da) | 2006-06-06 | 2016-05-09 | Crucell Holland Bv | Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf |
| CA2663388C (en) * | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| WO2008068246A1 (en) * | 2006-12-05 | 2008-06-12 | Crucell Holland B.V. | Liquid anti-rabies antibody formulations |
-
2007
- 2007-06-05 DK DK07765322.8T patent/DK2027155T3/da active
- 2007-06-05 EP EP11170742.8A patent/EP2395018B1/en active Active
- 2007-06-05 CN CN201310251872.0A patent/CN103351435B/zh not_active Expired - Fee Related
- 2007-06-05 US US12/227,029 patent/US8211431B2/en not_active Expired - Fee Related
- 2007-06-05 EP EP15196084.6A patent/EP3018142A1/en not_active Withdrawn
- 2007-06-05 EP EP07765322.8A patent/EP2027155B1/en active Active
- 2007-06-05 SI SI200731765A patent/SI2395018T1/sl unknown
- 2007-06-05 AU AU2007255384A patent/AU2007255384B2/en not_active Ceased
- 2007-06-05 HU HUE11170742A patent/HUE027099T2/hu unknown
- 2007-06-05 KR KR1020087031462A patent/KR101508390B1/ko not_active Expired - Fee Related
- 2007-06-05 EA EA201201650A patent/EA031202B1/ru not_active IP Right Cessation
- 2007-06-05 NZ NZ572773A patent/NZ572773A/en not_active IP Right Cessation
- 2007-06-05 WO PCT/EP2007/055527 patent/WO2007141274A2/en not_active Ceased
- 2007-06-05 EA EA200870593A patent/EA018030B1/ru not_active IP Right Cessation
- 2007-06-05 MX MX2008014977A patent/MX2008014977A/es active IP Right Grant
- 2007-06-05 CN CN2007800209231A patent/CN101460519B/zh not_active Expired - Fee Related
- 2007-06-05 DK DK11170742.8T patent/DK2395018T3/da active
- 2007-06-05 JP JP2009513679A patent/JP5574706B2/ja not_active Expired - Fee Related
- 2007-06-05 CA CA2881717A patent/CA2881717C/en active Active
- 2007-06-05 CA CA2654712A patent/CA2654712C/en active Active
-
2008
- 2008-12-02 IL IL195675A patent/IL195675A/en active IP Right Grant
-
2012
- 2012-02-15 US US13/397,606 patent/US8460666B2/en not_active Expired - Fee Related
-
2014
- 2014-07-01 JP JP2014136049A patent/JP5959576B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2027155T3 (da) | Humane bindingsmolekyler med dræberaktivitet mod stafylokokker og anvendelser deraf | |
| CN101460518B (zh) | 针对肠球菌和金黄色葡萄球菌具有杀伤活性的人结合分子及其应用 | |
| KR101485197B1 (ko) | 인플루엔자 바이러스 ｈ5ｎ1을 중화시킬 수 있는 인간 결합분자 및 그것의 용도 | |
| KR101790354B1 (ko) | 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도 | |
| KR101941724B1 (ko) | 계통발생군 1과 계통발생군 2의 인플루엔자 a형 바이러스 및 인플루엔자 b형 바이러스를 중화시킬 수 있는 인간 결합분자 | |
| CN101541832B (zh) | 能中和流感病毒h5n1的人结合分子及其应用 | |
| EP1928914A2 (en) | Method for preparing immunoglobulin libraries | |
| AU2006245734C1 (en) | Host cell specific binding molecules capable of neutralizing viruses and uses thereof | |
| KR20170042376A (ko) | 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 | |
| KR20140095558A (ko) | 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도 | |
| NZ618530B2 (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses |